XML 40 R31.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies (Details) - USD ($)
 6 Months Ended
Oct. 07, 2024
Aug. 27, 2024
Jun. 11, 2024
Jun. 30, 2024
Dec. 01, 2023
Commitments and Contingencies [Line Items]          
License consideration paid       $ 250,000  
Milestone payments due, description       (i) $750,000 payable following the end of a Phase II meeting with the FDA, with the amount to be reduced to $375,000 if toxicology studies must be repeated; (ii) $2 million following the earlier of U.S. Food and Drug Administration (“FDA”) marketing authorization of Quilience or Nolazol; (iii) 1% of any upfront and milestone payments, if any, from any sublicensees and (iv) $3 million as a one-time payment upon the Company’s product candidate reaching $250 million in cumulative sales.  
Aggregate amount         $ 492,723
Unpaid interest       $ 886,412.46  
Interest rate, percentage       6.00%  
Unpaid consulting fees     $ 35,171    
Forecast [Member]          
Commitments and Contingencies [Line Items]          
Unpaid interest   $ 110,179      
Interest rate, percentage   5.00%      
Forecast [Member] | Chad Hellman [Member]          
Commitments and Contingencies [Line Items]          
Unpaid consulting fees $ 36,940